Literature DB >> 29440147

The Balance Players of the Adaptive Immune System.

Mads Hald Andersen1,2.   

Abstract

Equilibrium between immune activation and suppression may be necessary to maintain immune homeostasis, because proinflammatory effector T cells (defined as antiregulatory T cells) counteract the functions of regulatory immune cells. These self-reactive T cells recognize human leukocyte antigen (HLA)-restricted epitopes derived from proteins expressed by regulatory immune cells such as IDO, PD-L1, PD-L2, or arginase. The activation of such proinflammatory effector T cells offers a novel way to directly target the tumor microenvironment, potentially giving them considerable clinical value, especially in patients with cancer. Vaccination against genetically stable cells with regular HLA expression is an attractive way to directly target immunosuppressive cells in addition to attracting proinflammatory cells into the tumor microenvironment. Importantly, vaccination toward IDO or PD-L1 to potentiate such T cells have proven safe, with minimal toxicity in the clinical phase I trials conducted thus far.Cancer Res; 78(6); 1379-82. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29440147     DOI: 10.1158/0008-5472.CAN-17-3607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Peripheral memory T cells specific for Arginase-1.

Authors:  Evelina Martinenaite; Shamaila Munir Ahmad; Inge Marie Svane; Mads Hald Andersen
Journal:  Cell Mol Immunol       Date:  2019-05-10       Impact factor: 11.530

Review 2.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

Review 3.  Tumor microenvironment antigens.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2022-09-29       Impact factor: 11.759

Review 4.  The T-win® technology: immune-modulating vaccines.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

5.  The red blood cell as a novel regulator of human B-cell activation.

Authors:  Charlotte S Lennon; Huan Cao; Andrew M Hall; Mark A Vickers; Robert N Barker
Journal:  Immunology       Date:  2021-05-06       Impact factor: 7.215

6.  Anti-regulatory T cells are natural regulatory effector T cells.

Authors:  Niels Ødum
Journal:  Cell Stress       Date:  2019-10-08

7.  The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.

Authors:  Stine Emilie Weis-Banke; Mie Linder Hübbe; Morten Orebo Holmström; Mia Aaboe Jørgensen; Simone Kloch Bendtsen; Evelina Martinenaite; Marco Carretta; Inge Marie Svane; Niels Ødum; Ayako Wakatsuki Pedersen; Özcan Met; Daniel Hargbøl Madsen; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2020-06-01       Impact factor: 8.110

8.  Inflammation induced PD-L1-specific T cells.

Authors:  Shamaila Munir; Mia Thorup Lundsager; Mia Aabroe Jørgensen; Morten Hansen; Trine Hilkjær Petersen; Charlotte Menne Bonefeld; Christina Friese; Özcan Met; Per Thor Straten; Mads Hald Andersen
Journal:  Cell Stress       Date:  2019-09-13

9.  Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

Authors:  Nicolai Grønne Jørgensen; Uffe Klausen; Jacob Handlos Grauslund; Carsten Helleberg; Thomas Granum Aagaard; Trung Hieu Do; Shamaila Munir Ahmad; Lars Rønn Olsen; Tobias Wirenfeldt Klausen; Marie Fredslund Breinholt; Morten Hansen; Evelina Martinenaite; Özcan Met; Inge Marie Svane; Lene Meldgaard Knudsen; Mads Hald Andersen
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

Review 10.  Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.

Authors:  Fabienne Maibach; Hassan Sadozai; S Morteza Seyed Jafari; Robert E Hunger; Mirjam Schenk
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.